1Flanagan N, Boyadjiev SA, Harper J, et al. Familial craniosynostosis,anal anomalies, and porokeralosis: CAP syndrome. J Med Genet, 1998,35(9) :763-766.
2Magee JW, McCalmont TH, LeBoit PE. Overexpression of p53 tumor suppressor protein in porokeratosis. Arch Dermatol, 1994, 130(2): 187-190.
3Urano Y, Susaki S, Ninomiya Y,et al. Immunohistochemical detection of P53 tumor suppressor protein in porokeratosis. J Dermatol, 1996, 23 ( 5 ):365-368.
4Ninomiya Y, Urano Y, Yoshimoto K, et al. P53 gene mutation analysis in porokeratosis and porokeratosis-associated squamous cell carcinoma. J Dermatol Sci, 1997,14(3): 173-178.
5Xia JH, Yang YF, Deng H, et al. Identification of a locus for disseminated superficial actinic porokeratosis at chromosome 12q23.2-24.1. J Invest Dermatol, 2000,11:(6):1071-1074.
6Mizukawa Y, Shiohara T. Porokeratosis in patients with hepatitis C virus infection: does hepatitis C vixus infection provide a link between porokeratosis and immunosuppression? Br J Dermatol, 1999,141 ( 1 ): 163-164.
7Kawakami T, Saito D, Takahashi K. Overexpression of p21waf/cip1 immunohistochemical staining in Bowen′s disease, but not in disseminated superficial porokeratosis. Br J Dermatol, 1999,141(4) :647-651.
8Quinn AG. p21watYcip1 and p53 expression in the skin-intertwined but not inseparable. Br J Dermatol, 1999,141(4) :613-616.
9Nelson C, Cowper S, Morgan M. p53, mdm-2, and p21 waf-1 in the pokeokeratoses. Am J Dermatopathol, 1999,21(5) :420-425.
10Happle R. Cancer proneness of linear porokeratosis may be explanned by allelic loss. Dermatology, 1997,195( 1 ) :20-25.
